The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor
Open accessAbstract
BI 224436 is an HIV-1 integrase inhibitor with effective antiviral activity that acts through a mechanism that is distinct from that of integrase strand transfer inhibitors (INSTIs). This 3-quinolineacetic acid derivative series was identified using an enzymatic integrase long terminal repeat (LTR) DNA 3′-processing assay. A combination of medicinal chemistry, parallel synthesis, and structure-guided drug design led to the identification of BI 224436 as a candidate for preclinical profiling. It has antiviral 50% effective concentrations (EC 50 s) of <15 nM against different HIV-1 laboratory strains and cellular cytotoxicity of >90 μM. BI 224436 also has a low, ∼2.1-fold decrease in antiviral potency in the presence of 50% human serum and, by virtue of a steep dose-response curve slope, exhibits serum-shifted EC 95 values ranging between 22 and 75 nM. Passage of virus in the presence of inhibitor selected for either A128T, A128N, or L102F primary resistance substitutions, all mapping to a conserved allosteric pocket on the catalytic core of integrase. BI 224436 also retains full antiviral activity against recombinant viruses encoding INSTI resistance substitutions N155S, Q148H, and E92Q. In drug combination studies performed in cellular antiviral assays, BI 224436 displays an additive effect in combination with most approved antiretrovirals, including INSTIs. BI 224436 has drug-like in vitro absorption, distribution, metabolism, and excretion (ADME) properties, including Caco-2 cell permeability, solubility, and low cytochrome P450 inhibition. It exhibited excellent pharmacokinetic profiles in rat (clearance as a percentage of hepatic flow [CL], 0.7%; bioavailability [ F ], 54%), monkey (CL, 23%; F , 82%), and dog (CL, 8%; F , 81%). Based on the excellent biological and pharmacokinetic profile, BI 224436 was advanced into phase 1 clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Resistance to ALLINIs maps to the IN CCD dimer interface in the vicinity of the LEDGF/p75 binding site171,173,179,182,188.”
From Structure and function of retroviral integrase (2022) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104 · cited 2×
“Cytotoxicity resulting in 50% death of cells (CC50) was determined using the tetrazolium salt MTT metabolic assay (32).”
MethodColman (2022) · doi:10.1073/pnas · Cited by 4,370
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., & Martin, M. A. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,834
Purification and Characterization
(2006) · Biomacromolecules · doi:10.1002/0470080124.ch3 · Cited by 2,309
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 2×
“Since the first proof of principle for the diketo acid integrase inhibitors in 2000, HIV integrase has been intensively studied as a target for drug discovery (8).”
BackgroundMethodRetroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678
Shaw, G. M., Hahn, B. H., Arya, S. K., Groopman, J. E., Gallo, R. C., & Wong-Staal, F. (1984) · Science · doi:10.1126/science.6095449 · Cited by 633
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544 · cited 1×
“transformed with Prichard and Shipmann’s MacSynergy II software using the Bliss independence model (38).”
MethodAn essential role for LEDGF/p75 in HIV integration
Llano, M., Saenz, D. T., Meehan, A., Wongthida, P., Peretz, M., Walker, W. H., Teo, W., & Poeschla, E. M. (2006) · Science · doi:10.1126/science.1132319 · Cited by 537
LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells
Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., & Engelborghs, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303594200 · Cited by 493
Research works printed but not linked: 1
- SchmidtNJEmmonsRW. 1989. General principles of laboratory diagnostic methods for viral, rickettsial and chlamydial infections, p 1–35. In SchmidtNJEmmonsRW (ed), Diagnostic procedures for rickettsial and chlamydial infections, 6th ed. American Public Health Association, Washington, DC.
Cited by
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
“…BI-224436 (Boehringer-Ingelheim, Gilead), which has low nanomolar antiviral potency, LE = 0.33, and LLE = 11.5 (Table 1) (Fader et al., 2014; Fenwick et al., 2014). tBPQAs were found in an HTS designed to identify inhibitors of IN-catalyzed 30 processing of DNA; structural studies later…”
BackgroundInfluentialLesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
Petta, I., Lievens, S., Libert, C., Tavernier, J., & De Bosscher, K. (2016) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 240
Block-And-Lock Strategies to Cure HIV Infection
Vansant, G., Bruggemans, A., Janssens, J., & Debyser, Z. (2020) · Viruses · doi:10.3390/v12010084 · Cited by 169
da Cunha, J., Maselli, L. M. F., Stern, A. C. B., Spada, C., & Bydlowski, S. P. (2015) · World Journal of Virology · doi:10.5501/wjv.v4.i2.56 · Cited by 167
Metadata
- Authors
- Fenwick, C., Amad, M., Bailey, M. D., Bethell, R., Bös, M., Bonneau, P., Cordingley, M., Coulombe, R., Duan, J., Edwards, P., Fader, L. D., Faucher, A.-M., Garneau, M., Jakalian, A., Kawai, S., Lamorte, L., LaPlante, S., Luo, L., Mason, S., Poupart, M.-A., Rioux, N., Schroeder, P., Simoneau, B., Tremblay, S., Tsantrizos, Y., Witvrouw, M., & Yoakim, C.
- Affiliations
- Boehringer Ingelheim (Canada) (CA)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-06
- Volume
- 58
- Issue
- 6
- Pages
- 3233-3244
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC4068430
- OpenAlex
- W2131078522
- Cited by
- 99
- References
- 56
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 4 · 2023: 12 · 2022: 11 · 2021: 9 · 2020: 10 · 2019: 6 · 2018: 6 · 2017: 8 · 2016: 10 · 2015: 8 · 2014: 7
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1 integrase inhibitors, integrase strand transfer inhibitors, integrase resistance mutations, allosteric pocket, antiviral activity, drug resistance, combination therapy, pharmacokinetics, ADME properties, structure-based drug design
- MeSH terms
- Animals, Cloning, Molecular, DNA, Viral, Humans, Virus Replication, HIV-1, Caco-2 Cells, Anti-HIV Agents, HIV Integrase, HIV Integrase Inhibitors, Amino Acid Substitution, Hepatocytes, Drug Resistance, Viral, Serum, Mice, Rats, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor. https://app.cochat.ai/papers/10.1128/aac.02719-13
- The paper
- Fenwick, C., Amad, M., Bailey, M. D., Bethell, R., Bös, M., Bonneau, P., Cordingley, M., Coulombe, R., Duan, J., Edwards, P., Fader, L. D., Faucher, A.-M., Garneau, M., Jakalian, A., Kawai, S., Lamorte, L., LaPlante, S., Luo, L., Mason, S., . . . Yoakim, C. (2014). Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.02719-13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.